Back to Agenda
Why is this Discussion of Audit Methods Important?
Session Chair(s)
Annette Schmid, PhD
Senior Director Scientific & Medical Services, Head of Oncology Imaging Strategy, PAREXEL International, United States
The purpose for this session is to provide a broad historical perspective on changes in the clinical trial landscape e.g. the way trials are run, the speed of trials, preservation of study end points, evolving trial design and technology. A context will be established for the development/evolution of medical imaging interpretation in oncology clinical trials.
Speaker(s)
Jie Zhang
Senior Manager, Biostatistics, Gilead, China
Why is this Discussion of Audit Methods Important?
Annette Schmid, PhD
Senior Director Scientific & Medical Services, Head of Oncology Imaging Strategy, PAREXEL International, United States
Q&A Discussion - Panelists
David I. Raunig
Senior Vice President, Medical & Scientific Affairs, ICON, United States
Susanta Sarkar
President, Cadenzamed LLC, United States
Andrea Perrone, MD
Head of Clinical Imaging, Translational Medicine, Merck, United States
Steven Sun, PhD
Director, Janssen R&D, United States
Have an account?